Clinical Trial Update: A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus [Phase 1]

View source ↗

Summary

This clinical trial update reports that CLN-978, a subcutaneously administered CD19-directed T cell engager, is being studied in subjects with systemic lupus er…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• CLN-978

Snippet

Sponsor: Cullinan Therapeutics Inc. | Conditions: SLE, SLE (Systemic Lupus) | Phase 1 | Status: RECRUITING